An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued
May 01
Australian (ASX) Biotech Industry Analysis
UpdatedMay 02, 2024
DataAggregated Company Financials
Companies33
- 7D-1.2%
- 3M-5.7%
- 1Y-7.4%
- YTD-3.1%
Over the last 7 days, the Biotech industry has dropped 1.2%, driven by CSL declining 1.1%. On the other hand Mesoblast is actually up 17%. Overall the industry is down 7.4% in 12 months. Earnings are forecast to grow by 16% annually.
Industry Valuation and Performance
Has the Australian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 02 May 2024 | AU$142.3b | AU$22.6b | AU$3.3b | 30x | 43x | 6.3x |
| Sat, 30 Mar 2024 | AU$147.5b | AU$22.5b | AU$3.3b | 30.3x | 44.7x | 6.5x |
| Mon, 26 Feb 2024 | AU$144.9b | AU$22.4b | AU$3.3b | 36.6x | 43.7x | 6.5x |
| Wed, 24 Jan 2024 | AU$149.0b | AU$20.9b | AU$2.8b | 34x | 53.8x | 7.1x |
| Fri, 22 Dec 2023 | AU$143.6b | AU$20.3b | AU$2.7b | 34.2x | 53.5x | 7.1x |
| Sun, 19 Nov 2023 | AU$131.6b | AU$21.1b | AU$2.8b | 32x | 46.9x | 6.3x |
| Tue, 17 Oct 2023 | AU$123.8b | AU$21.8b | AU$2.9b | 29.8x | 43.2x | 5.7x |
| Thu, 14 Sep 2023 | AU$137.7b | AU$21.4b | AU$2.8b | 32.4x | 49.1x | 6.4x |
| Sat, 12 Aug 2023 | AU$136.3b | AU$18.4b | AU$2.4b | 38.4x | 57.1x | 7.4x |
| Mon, 10 Jul 2023 | AU$137.4b | AU$18.0b | AU$2.3b | 36.7x | 59.2x | 7.6x |
| Wed, 07 Jun 2023 | AU$157.2b | AU$18.1b | AU$2.3b | 41.3x | 67.3x | 8.7x |
| Fri, 05 May 2023 | AU$153.9b | AU$18.0b | AU$2.3b | 41.2x | 66.3x | 8.6x |
| Sun, 02 Apr 2023 | AU$146.9b | AU$18.0b | AU$2.3b | 40x | 63.4x | 8.2x |
| Tue, 28 Feb 2023 | AU$151.5b | AU$17.7b | AU$2.3b | 41.5x | 65.8x | 8.5x |
| Thu, 26 Jan 2023 | AU$152.1b | AU$15.3b | AU$2.4b | 55.1x | 63x | 10x |
| Sat, 24 Dec 2022 | AU$147.5b | AU$16.1b | AU$2.6b | 46.1x | 57.5x | 9.2x |
| Mon, 21 Nov 2022 | AU$150.5b | AU$16.1b | AU$2.6b | 43.5x | 58.9x | 9.4x |
| Wed, 19 Oct 2022 | AU$141.0b | AU$17.1b | AU$2.7b | 40.7x | 51.3x | 8.3x |
| Fri, 16 Sep 2022 | AU$146.7b | AU$15.9b | AU$2.5b | 46x | 57.7x | 9.2x |
| Sun, 14 Aug 2022 | AU$149.6b | AU$15.2b | AU$2.7b | 41.7x | 54.9x | 9.9x |
| Tue, 12 Jul 2022 | AU$145.8b | AU$15.7b | AU$2.8b | 37.5x | 51.4x | 9.3x |
| Thu, 09 Jun 2022 | AU$135.2b | AU$15.0b | AU$2.7b | 35.2x | 50.1x | 9x |
| Sat, 07 May 2022 | AU$135.6b | AU$15.1b | AU$2.8b | 35.7x | 49.1x | 9x |
| Mon, 04 Apr 2022 | AU$135.7b | AU$14.4b | AU$2.6b | 39.1x | 52.2x | 9.5x |
| Wed, 02 Mar 2022 | AU$134.5b | AU$14.9b | AU$2.6b | 41.3x | 52.1x | 9x |
| Fri, 28 Jan 2022 | AU$128.8b | AU$14.6b | AU$2.8b | 36x | 46.3x | 8.8x |
| Sun, 26 Dec 2021 | AU$152.1b | AU$14.5b | AU$2.8b | 42.6x | 55.1x | 10.5x |
| Tue, 23 Nov 2021 | AU$156.9b | AU$14.4b | AU$2.7b | 44x | 57.4x | 10.9x |
| Thu, 21 Oct 2021 | AU$147.9b | AU$14.0b | AU$2.6b | 42.7x | 56.1x | 10.6x |
| Sat, 18 Sep 2021 | AU$153.8b | AU$14.4b | AU$2.7b | 43.2x | 56.7x | 10.7x |
| Mon, 16 Aug 2021 | AU$146.3b | AU$14.0b | AU$2.6b | 42.7x | 55.7x | 10.5x |
| Mon, 31 May 2021 | AU$142.6b | AU$13.5b | AU$2.8b | 39.9x | 50.3x | 10.5x |
Price to Earnings Ratio
46.8x
Current Industry PE
- Investors are pessimistic on the Australian Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 43.0x which is lower than its 3-year average PE of 54.2x.
- The 3-year average PS ratio of 8.6x is higher than the industry's current PS ratio of 6.3x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have grown 5.3% per year over the last three years.
- Revenues for these companies have grown 19% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Australian Healthcare industry?
| AU Market | -1.54% | |
| Healthcare | -1.12% | |
| Biotech | -1.25% | |
| Biotech | -1.25% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| MSB Mesoblast | AU$1.07 | 16.9% +AU$176.9m | 8.6% | PS106.9x | |
| PYC PYC Therapeutics | AU$0.10 | 7.5% +AU$50.7m | 61.3% | PS22x | |
| ACW Actinogen Medical | AU$0.038 | 31.0% +AU$20.9m | -41.5% | PS18.4x | |
| IMU Imugene | AU$0.085 | 2.4% +AU$14.6m | -29.2% | PS41.4x | |
| CYP Cynata Therapeutics | AU$0.23 | 11.9% +AU$4.5m | 51.6% | PS17.6x |
